Login / Signup

Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience.

Silvia GiordanoPaolo DapavoMichela OrtoncelliElena StroppianaAnna VerronePietro QuaglinoSimone RiberoLuca Mastorino
Published in: Journal of clinical medicine (2023)
Our data support the evidence that an interclass switch among IL-17 inhibitors is a safe and effective therapeutic option for these patients.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • electronic health record
  • big data
  • atopic dermatitis